Heart failure & cardiomyopathies
Pharmacoutilization and Adherence to Sacubitril/Valsartan in Real World: The REAL.IT Study in HFrEF
Authors' conclusion
Real-world data on the use of sacubitril/valsartan in clinical practice in Italy show a rapid titration to the target dose, high therapeutic adherence enabling a good level of therapeutic management in line with ESC guidelines for patients with reduced ejection fraction.
Study context
- Population
- Patients with HFrEF prescribed sacubitril/valsartan in real-world clinical practice in Italy924 followed up for 12 months
- Participants
- 948 patients
- Outcome
- Pharmacoutilization of sacubitril/valsartan
- Follow-up
- 1 year
Methodological detailsobservational, non-interventional, electronic medical records, 9 specialized hospital heart failure (HF) centres in Italy
- Observational
- Non-interventional
- Electronic medical records
- 9 specialized hospital HF centres in Italy
Main finding
As reported in the abstract
- Reached target dose of 97/103 mg
- 398 (45.2%)
- Mean time to target dose
- 6.9 (SD = 6.2) weeks
- Change in dose during follow-up
- Approximatively 50%
- Persistent during last 3 months of follow-up
- 158 (70.2%)
- Full adherence (387 with data)
- 205 (53%)
- Discontinuation, mainly due to hypotension
- 102/717 patients, 14.2%
- Mean time to discontinuation
- 34.3 (SD = 28.7) weeks
- HF add-on drug(s) concomitant (606 with data)
- 434 patients (71.6%)
Observational data: associations, not effects.
Further findings
HF-related hospitalization, non-persistent vs persistent · during follow-up · numerically higher in non-persistent
P = 0.405
- HF-related hospitalization, non-persistent vs persistent: 16/67 vs 30/158
Reasons for not reaching target dose
Patients
- BP and hypotension
- 61 (65%)
- Worsening of CKD
- 10 (10.6%)
Persistence during last 4 months of follow-up (sensitivity analysis)
- Persistent
- 162 patients (72.0%)
- Sensitivity analysis
Original publication
Pharmacoutilization and Adherence to Sacubitril/Valsartan in Real World: The REAL.IT Study in HFrEF. ESC Heart Fail. Published 1 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →